Testing effectiveness (Phase 2)Study completedNCT01151423
What this trial is testing
Study to Assess Efficacy and Safety of Anti-von Willebrand Factor (vWF) Nanobody in Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)
Who this might be right for
Acquired Thrombotic Thrombocytopenic Purpura
Ablynx, a Sanofi company 75